
Katherine Kurnit, MD, OBGYN oncology fellow at the University of Texas MD Anderson Cancer Center, compares the benefit of gastrointestinal-based versus gynecologic-based adjuvant chemotherapy regimens in patients with mucinous ovarian cancer.

Your AI-Trained Oncology Knowledge Connection!


Published: January 19th 2019 | Updated: